492 related articles for article (PubMed ID: 24834925)
1. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.
Brunner HI; Ruperto N; Zuber Z; Keane C; Harari O; Kenwright A; Lu P; Cuttica R; Keltsev V; Xavier RM; Calvo I; Nikishina I; Rubio-Pérez N; Alexeeva E; Chasnyk V; Horneff G; Opoka-Winiarska V; Quartier P; Silva CA; Silverman E; Spindler A; Baildam E; Gámir ML; Martin A; Rietschel C; Siri D; Smolewska E; Lovell D; Martini A; De Benedetti F; ;
Ann Rheum Dis; 2015 Jun; 74(6):1110-7. PubMed ID: 24834925
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
Brunner HI; Ruperto N; Zuber Z; Cuttica R; Keltsev V; Xavier RM; Burgos-Vargas R; Penades IC; Silverman ED; Espada G; Zavaler MF; Kimura Y; Duarte C; Job-Deslandre C; Joos R; Douglass W; Wimalasundera S; Bharucha KN; Wells C; Lovell DJ; Martini A; de Benedetti F;
Arthritis Rheumatol; 2021 Mar; 73(3):530-541. PubMed ID: 32951358
[TBL] [Abstract][Full Text] [Related]
3. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.
De Benedetti F; Brunner HI; Ruperto N; Kenwright A; Wright S; Calvo I; Cuttica R; Ravelli A; Schneider R; Woo P; Wouters C; Xavier R; Zemel L; Baildam E; Burgos-Vargas R; Dolezalova P; Garay SM; Merino R; Joos R; Grom A; Wulffraat N; Zuber Z; Zulian F; Lovell D; Martini A; ;
N Engl J Med; 2012 Dec; 367(25):2385-95. PubMed ID: 23252525
[TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.
Brunner HI; Ruperto N; Tzaribachev N; Horneff G; Chasnyk VG; Panaviene V; Abud-Mendoza C; Reiff A; Alexeeva E; Rubio-Pérez N; Keltsev V; Kingsbury DJ; Del Rocio Maldonado Velázquez M; Nikishina I; Silverman ED; Joos R; Smolewska E; Bandeira M; Minden K; van Royen-Kerkhof A; Emminger W; Foeldvari I; Lauwerys BR; Sztajnbok F; Gilmer KE; Xu Z; Leu JH; Kim L; Lamberth SL; Loza MJ; Lovell DJ; Martini A;
Ann Rheum Dis; 2018 Jan; 77(1):21-29. PubMed ID: 28507219
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.
Yokota S; Imagawa T; Mori M; Miyamae T; Aihara Y; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
Lancet; 2008 Mar; 371(9617):998-1006. PubMed ID: 18358927
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis.
Frampton JE
Paediatr Drugs; 2013 Dec; 15(6):515-31. PubMed ID: 24155139
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.
Lovell DJ; Brunner HI; Reiff AO; Jung L; Jarosova K; Němcová D; Mouy R; Sandborg C; Bohnsack JF; Elewaut D; Gabriel C; Higgins G; Kone-Paut I; Jones OY; Vargová V; Chalom E; Wouters C; Lagunes I; Song Y; Martini A; Ruperto N
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665432
[TBL] [Abstract][Full Text] [Related]
10. Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial.
Bharucha KN; Brunner HI; Calvo Penadés I; Nikishina I; Rubio-Pérez N; Oliveira S; Kobusinska K; Schmeling H; Sztajnbok F; Weller-Heinemann F; Zholobova E; Zulian F; Allen R; Chaitow J; Frane J; Wells C; Ruperto N; De Benedetti F;
J Rheumatol; 2018 Aug; 45(8):1173-1179. PubMed ID: 29961686
[TBL] [Abstract][Full Text] [Related]
11. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
Ruperto N; Brunner HI; Synoverska O; Ting TV; Mendoza CA; Spindler A; Vyzhga Y; Marzan K; Grebenkina L; Tirosh I; Imundo L; Jerath R; Kingsbury DJ; Sozeri B; Vora SS; Prahalad S; Zholobova E; Butbul Aviel Y; Chasnyk V; Lerman M; Nanda K; Schmeling H; Tory H; Uziel Y; Viola DO; Posner HB; Kanik KS; Wouters A; Chang C; Zhang R; Lazariciu I; Hsu MA; Suehiro RM; Martini A; Lovell DJ;
Lancet; 2021 Nov; 398(10315):1984-1996. PubMed ID: 34767764
[TBL] [Abstract][Full Text] [Related]
13. Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis.
Pardeo M; Wang J; Ruperto N; Alexeeva E; Chasnyk V; Schneider R; Horneff G; Huppertz HI; Minden K; Onel K; Zemel L; Martin A; Koné-Paut I; Siamopoulou-Mavridou A; Silva CA; Porter-Brown B; Bharucha KN; Brunner HI; De Benedetti F;
J Rheumatol; 2019 Sep; 46(9):1117-1126. PubMed ID: 30824645
[TBL] [Abstract][Full Text] [Related]
14. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis.
Imagawa T; Yokota S; Mori M; Miyamae T; Takei S; Imanaka H; Nerome Y; Iwata N; Murata T; Miyoshi M; Nishimoto N; Kishimoto T
Mod Rheumatol; 2012 Feb; 22(1):109-15. PubMed ID: 21667343
[TBL] [Abstract][Full Text] [Related]
16. Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial.
Opoka-Winiarska V; Żuber Z; Alexeeva E; Chasnyk V; Nikishina I; Dębowska G; Smolewska E
Clin Rheumatol; 2018 Jul; 37(7):1807-1816. PubMed ID: 29654485
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials.
Malattia C; Ruperto N; Pederzoli S; Palmisani E; Pistorio A; Wouters C; Dolezalova P; Flato B; Garay S; Giancane G; Wells C; Douglass W; Brunner HI; De Benedetti F; Ravelli A;
Arthritis Res Ther; 2020 Sep; 22(1):211. PubMed ID: 32912276
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis.
Grönlund MM; Remes-Pakarinen T; Kröger L; Markula-Patjas K; Backström M; Putto-Laurila A; Aalto K; Vähäsalo P
Rheumatology (Oxford); 2020 Apr; 59(4):732-741. PubMed ID: 31359057
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab for treating juvenile idiopathic arthritis.
Turnier JL; Brunner HI
Expert Opin Biol Ther; 2016; 16(4):559-66. PubMed ID: 26848760
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI
Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
